The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few months.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

Ansa is accepting orders for synthetic DNA constructs ranging from 7.5 kb up to 50 kb for various applications.

The virus likely reached humans not via bat migration but through the wildlife trade—contradicting hypotheses that it may ...

BMS pledges $40B over five years to boost U.S. R&D, tech innovation, and pharmaceutical manufacturing under CEO Christopher ...

Discovery of innate immune receptor "brake" Siglec-E offers a novel therapeutic target to prevent organ transplant rejection ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...

Researchers expect LICONN technology will be broadly useful to enable high-resolution tissue analysis in other organs and ...